NASDAQ:BIAFW bioAffinity Technologies (BIAFW) Stock Price, News & Analysis $0.12 -0.01 (-4.76%) As of 01:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About bioAffinity Technologies Stock (NASDAQ:BIAFW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIAFW alerts:Sign Up Key Stats Today's Range$0.13▼$0.1350-Day Range$0.10▼$0.3152-Week Range$0.05▼$0.81Volume1,973 shsAverage Volume2,422 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview bioAffinity Technologies, Inc. is a clinical-stage medical device company developing an extracorporeal immunoadsorption platform intended to treat Gram-negative sepsis and other severe inflammatory conditions. The company’s technology employs specialized sorbent cartridges designed to selectively bind and remove circulating endotoxins and inflammatory mediators from the bloodstream, with the goal of supporting critical care interventions and improving patient outcomes. In preclinical studies, bioAffinity’s hemoperfusion devices have demonstrated the ability to capture lipopolysaccharides released by Gram-negative bacteria, leading to reductions in pro-inflammatory cytokines and enhanced survival rates in animal models. Building on these results, the company has initiated early‐phase human trials in collaboration with clinical research centers to assess the safety, tolerability and preliminary efficacy of its lead immunoadsorption cartridge in sepsis patients. bioAffinity Technologies is pursuing regulatory clearances in North America and Europe, working toward U.S. Food and Drug Administration authorization and CE marking for its blood purification system. To support these efforts, the company partners with hospitals and research institutions to conduct clinical evaluations and optimize manufacturing processes for scalable production ahead of potential commercialization. Founded with a mission to address unmet needs in critical care, bioAffinity leverages a leadership team with expertise in biomedical engineering, immunology and critical care medicine. The company remains focused on advancing its pipeline, forging strategic collaborations within the healthcare industry and ultimately delivering its innovative blood purification therapies to patients worldwide.AI Generated. May Contain Errors. Read More Receive BIAFW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIAFW Stock News HeadlinesWallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million OfferingJune 19, 2026 | finanznachrichten.deMultidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy ...June 2, 2026 | finance.yahoo.comAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more than the entire dot-com buildout combined, from just four companies, in a single year. That capital flows down through chipmakers, network builders, and small data infrastructure companies most investors will never read a headline about. Chris Rowe, who spent 30 years tracking institutional money flows, has identified the companies positioned to capture this wave before it becomes a mainstream story.July 6 at 1:00 AM | True Market Insiders (Ad)bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung TechnologyMay 27, 2026 | finance.yahoo.combioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16April 7, 2026 | finance.yahoo.combioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026April 1, 2026 | tmcnet.comBioAffinity Technologies stock cools off after strong Friday rally - here's whyMarch 16, 2026 | msn.combioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath(R) LungMarch 13, 2026 | marketwatch.comSee More Headlines BIAFW Stock Analysis - Frequently Asked Questions How have BIAFW shares performed this year? bioAffinity Technologies' stock was trading at $0.35 at the beginning of 2026. Since then, BIAFW stock has decreased by 65.1% and is now trading at $0.1220. How do I buy shares of bioAffinity Technologies? Shares of BIAFW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/06/2026Next Earnings (Estimated)8/19/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 BIAFW's financial health is in the Yellow zone, according to TradeSmith. BIAFW has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryBusiness Services Current SymbolNASDAQ:BIAFW CIK1712762 Webwww.bioaffinitytech.com Phone210 698 5334FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$5.61 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BIAFW) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | SponsoredI Turned $57k Into $1.87MI spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...Decentralized Masters | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
